Overlooked KCNQ4 variants augment the risk of hearing loss
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Pathogenic variants of KCNQ4 cause symmetrical, late-onset, progressive, high-frequency-affected hearing loss, which eventually involves all frequencies with age. To understand the contribution of KCNQ4 variants to hearing loss, we analyzed whole-exome and genome sequencing data from patients with hearing loss and individuals whose hearing phenotypes were unknown. In KCNQ4, we identified seven missense variants and one deletion variant in 9 hearing loss patients and 14 missense variants in the Korean population with an unknown hearing loss phenotype. The p.R420W and p.R447W variants were found in both cohorts. To investigate the effects of these variants on KCNQ4 function, we performed whole-cell patch clamping and examined their expression levels. Except for p.G435Afs*61, all KCNQ4 variants exhibited normal expression patterns similar to those of wild-type KCNQ4. The p.R331Q, p.R331W, p.G435Afs*61, and p.S691G variants, which were identified in patients with hearing loss, showed a potassium (K+) current density lower than or similar to that of p.L47P, a previously reported pathogenic variant. The p.S185W and p.R216H variants shifted the activation voltage to hyperpolarized voltages. The channel activity of the p.S185W, p.R216H, p.V672M, and p.S691G KCNQ4 proteins was rescued by the KCNQ activators retigabine or zinc pyrithione, whereas p.G435Afs*61 KCNQ4 proteins were partially rescued by sodium butyrate, a chemical chaperone. Additionally, the structure of the variants predicted using AlphaFold2 showed impaired pore configurations, as did the patch-clamp data. Our findings suggest that KCNQ4 variants may be overlooked in hearing loss that starts in adulthood. Some of these variants are medically treatable; hence, genetic screening for KCNQ4 is important.
Abstract
Pathogenic variants of KCNQ4 cause symmetrical, late-onset, progressive, high-frequency-affected hearing loss, which eventually involves all frequencies with age. To understand the contribution of KCNQ4 variants to hearing loss, we analyzed whole-exome and genome sequencing data from patients with hearing loss and individuals whose hearing phenotypes were unknown. In KCNQ4, we identified seven missense variants and one deletion variant in 9 hearing loss patients and 14 missense variants in the Korean population with an unknown hearing loss phenotype. The p.R420W and p.R447W variants were found in both cohorts. To investigate the effects of these variants on KCNQ4 function, we performed whole-cell patch clamping and examined their expression levels. Except for p.G435Afs*61, all KCNQ4 variants exhibited normal expression patterns similar to those of wild-type KCNQ4. The p.R331Q, p.R331W, p.G435Afs*61, and p.S691G variants, which were identified in patients with hearing loss, showed a potassium (K+) current density lower than or similar to that of p.L47P, a previously reported pathogenic variant. The p.S185W and p.R216H variants shifted the activation voltage to hyperpolarized voltages. The channel activity of the p.S185W, p.R216H, p.V672M, and p.S691G KCNQ4 proteins was rescued by the KCNQ activators retigabine or zinc pyrithione, whereas p.G435Afs*61 KCNQ4 proteins were partially rescued by sodium butyrate, a chemical chaperone. Additionally, the structure of the variants predicted using AlphaFold2 showed impaired pore configurations, as did the patch-clamp data. Our findings suggest that KCNQ4 variants may be overlooked in hearing loss that starts in adulthood. Some of these variants are medically treatable; hence, genetic screening for KCNQ4 is important.
참고문헌 (42)
- Fortnum, H. M., "Prevalence of permanent childhood hearing impairment in the United Kingdom and implications for universal neonatal hearing screening : questionnaire based ascertainment study", Br. Med. J, 323, pp.536~540 (2001)
- Kral, A., "Profound deafness in childhood", N. Engl. J. Med, 363, pp.1438~1450 (2010)
- Morton, C. C., "Newborn hearing screening—a silent revolution", N. Engl. J. Med, 354, pp.2151~2164 (2006)
- Azaiez, H., "Genomic landscape and mutational signatures of deafnessassociated genes", Am. J. Hum. Genet, 103, pp.484~497 (2018)
- Cunningham, L. L., "Hearing loss in adults", N. Engl. J. Med, 377, pp.2465~2473 (2017)
- Oh, K. S., "COCH-related autosomal dominant nonsyndromic hearing loss : a phenotype–genotype study", Hum. Genet, 141, pp.889~901 (2021)
- Rim, J. H., "Activation of KCNQ4 as a therapeutic strategy to treat hearing loss", Int. J. Mol. Sci, 22, pp.2510~ (2021)
- Koh, Y. I., "OSBPL2 mutations impair autophagy and lead to hearing loss, potentially remedied by rapamycin", Autophagy, 18, pp.2593~2614 (2022)
- Kharkovets, T., "KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway", Proc. Natl. Acad. Sci. U. S. A, 97, pp.4333~4338 (2000)
- Kubisch, C., "KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness", Cell, 96, pp.437~446 (1999)
- Holt, J. R., "Dominant-negative inhibition of M-like potassium conductances in hair cells of the mouse inner ear", J. Neurosci, 27, pp.8940~8951 (2007)
- Carignano, C., "Inner hair cell and neuron degeneration contribute to hearing loss in a DFNA2-like mouse model", Neuroscience, 410, pp.202~216 (2019)
- Kharkovets, T., "Mice with altered KCNQ4 K+ channels implicate sensory outer hair cells in human progressive deafness", EMBO J, 25, pp.642~652 (2006)
- Brown, D. A, "Kv7(KCNQ)potassium channels that are mutated in human diseases", J. Physiol, 586, pp.1781~ (2008)
- Gao, Y., "Impaired surface expression and conductance of the KCNQ4 channel lead to sensorineural hearing loss", J. Cell. Mol. Med, 17, pp.889~900 (2013)
- Jinsei Jung, "Rare KCNQ4 variants found in public databases underlie impaired channel activity that may contribute to hearing impairment", Experimental and Molecular Medicine, 51, pp.1~12 (2019), 생화학분자생물학회[DOI]
- Shin, D. H., "A recurrent mutation in KCNQ4 in Korean families with nonsyndromic hearing loss and rescue of the channel activity by KCNQ activators", Hum. Mutat, 40, pp.335~346 (2019)
- Jung, J., "Whole-exome sequencing identifies two novel mutations in KCNQ4 in individuals with nonsyndromic hearing loss", Sci. Rep, 8, pp.16659~ (2018)
- Gee, H. Y., "Rescue of ΔF508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway", Cell, 146, pp.746~760 (2011)
- Park, H., "IRE1α kinase–mediated unconventional protein secretion rescues misfolded CFTR and pendrin", Sci. Adv, 6, pp.eaax9914~ (2020)
- Gee, H. Y., "Syntaxin 16 binds to cystic fibrosis transmembrane conductance regulator and regulates its membrane trafficking in epithelial cells", J. Biol. Chem, 285, pp.35519~35527 (2010)
- Horovitz, A., "Double-mutant cycles : a powerful tool for analyzing protein structure and function", Fold. Des, 1, pp.R121~R126 (1996)
- Hidalgo, P., "Revealing the Architecture of a K+ Channel Pore through Mutant Cycles with a Peptide Inhibitor", Science, 268, pp.307~310 (1995)
- Jumper, J., "Highly accurate protein structure prediction with AlphaFold", Nature, 596, pp.583~589 (2021)
- Mirdita, M., "ColabFold : making protein folding accessible to all", Nat. Methods, 19, pp.679~682 (2022)
- Smart, O. S., "HOLE : a program for the analysis of the pore dimensions of ion channel structural models", J. Mol. Graph, 14, pp.354~360 (1996)
- Pettersen, E. F., "UCSF ChimeraX : Structure visualization for researchers, educators, and developers", Protein Sci, 30, pp.70~82 (2021)
- Jo, S., "CHARMM-GUI : a web-based graphical user interface for CHARMM", J. Comput. Chem, 29, pp.1859~1865 (2008)
- Jo, S., "PBEQ-Solver for online visualization of electrostatic potential of biomolecules", Nucleic Acids Res, 36, pp.W270~W275 (2008)
- Brooks, B. R., "Charmm—a program for macromolecular energy, minimization, and dynamics calculations", J. Comput. Chem, 4, pp.187~217 (1983)
- Im, W., "Continuum Solvation Model : computation of electrostatic forces from numerical solutions to the Poisson-Boltzmann equation", Comput. Phys. Commun, 111, pp.59~75 (1998)
- Sang-Yeon Lee, "Novel KCNQ4 variants in different functional domains confer genotype- and mechanism-based therapeutics in patients with nonsyndromic hearing loss", Experimental and Molecular Medicine, 53, pp.1~13 (2021), 생화학분자생물학회[DOI]
- Schenzer, A., "Molecular determinants of KCNQ(Kv7)K+ channel sensitivity to the anticonvulsant retigabine", J. Neurosci, 25, pp.5051~5060 (2005)
- Moyer, B. D., "Butyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cells", Am. J. Physiol. Renal Physiol, 277, pp.F271~F276 (1999)
- Li, T., "Structural Basis for the Modulation of Human KCNQ4 by Small-Molecule Drugs", Mol. Cell, 81, pp.25~37 (2021)
- Zheng, Y., "Structural insights into the lipid and ligand regulation of a human neuronal KCNQ channel", Neuron, 110, pp.237~247 (2022)
- Jung, J., "Whole-exome sequencing identifies two novel mutations in KCNQ4in individuals with nonsyndromic hearing loss", Sci. Rep, 8, pp.1~11 (2018)
- Chang, A., "A calmodulin C-Lobe Ca(2+)-dependent switch governs Kv7channel function", Neuron, 97, pp.836~852 (2018)
- Schroder, R. L., "KCNQ4 channel activation by BMS-204352 and retigabine", Neuropharmacology, 40, pp.888~898 (2001)
- Tatulian, L., "Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine", J. Neurosci, 21, pp.5535~5545 (2001)
- Xiong, Q., "Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants", Nat. Chem. Biol, 3, pp.287~296 (2007)
- heptane-2-carboxamides: characterization of ML213 as a Novel KCNQ2 and KCNQ4 potassium channel opener, "ACS Chem. Neurosci", 2011, 572~577